Achillion Pharmaceuticals, Inc.  

(Public, NASDAQ:ACHN)   Watch this stock  
Find more results for ACHN
-0.38 (-5.67%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.24 - 6.71
52 week 6.04 - 12.94
Open 6.61
Vol / Avg. 2.56M/1.91M
Mkt cap 814.02M
P/E     -
Div/yield     -
EPS -0.45
Shares 136.54M
Beta 2.21
Inst. own 92%
Mar 3, 2016
Q4 2015 Achillion Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 11, 2016
Achillion Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference - 11:35AM EST - Add to calendar
Dec 6, 2015
Achillion Pharmaceuticals Inc Complement Factor D Symposium
Nov 11, 2015
Achillion Pharmaceuticals Inc at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 77.64% -
Operating margin 50.21% -
EBITD margin - -
Return on average assets 28.25% -43.23%
Return on average equity 31.36% -46.56%
Employees 67 -
CDP Score - -


300 George St
NEW HAVEN, CT 06511-6624
United States - Map
+1-203-6247000 (Phone)
+1-203-6247003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Officers and directors

David I. Scheer Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Milind S. Deshpande Ph.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Mary Kay Fenton CPA Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Joel C. Barrish Executive Vice President, Chief Scientific Officer
Bio & Compensation  - Reuters
Martha E. Manning Esq., Executive Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
David Apelian M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Joseph Truitt Executive Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Amy Jennings Senior Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Michael D. Kishbauch Director
Age: 66
Bio & Compensation  - Reuters
Frank A. G. M. Verwiel M.D. Director
Age: 53
Bio & Compensation  - Reuters